Business Description
Sanofi SA
SIC : 2834
ISIN : FR0000120578
Share Class Description:
CHIX:SANp: Ordinary SharesCompare
Compare
Traded in other countries / regions
SAN.FranceSNY.USA0O59.UKSNW.GermanySNW.BulgariaSNY N.Mexico1SAN.ItalySANO.Austria IPO Date
2009-01-30Description
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.44 | |||||
| Equity-to-Asset | 0.58 | |||||
| Debt-to-Equity | 0.23 | |||||
| Debt-to-EBITDA | 1.62 | |||||
| Interest Coverage | 12.63 | |||||
| Piotroski F-Score | 9/9 | |||||
| Altman Z-Score | 2.11 | |||||
| Beneish M-Score | -2.58 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 4.2 | |||||
| 3-Year EBITDA Growth Rate | -1.4 | |||||
| 3-Year EPS without NRI Growth Rate | 1.5 | |||||
| 3-Year FCF Growth Rate | -11.4 | |||||
| 3-Year Book Growth Rate | 4.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 17.29 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 5.95 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 88.36 | |||||
| 9-Day RSI | 86.72 | |||||
| 14-Day RSI | 84.38 | |||||
| 3-1 Month Momentum % | 10.87 | |||||
| 6-1 Month Momentum % | -2.04 | |||||
| 12-1 Month Momentum % | 16.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.46 | |||||
| Quick Ratio | 1.14 | |||||
| Cash Ratio | 0.27 | |||||
| Days Inventory | 273.7 | |||||
| Days Sales Outstanding | 67.64 | |||||
| Days Payable | 205.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.52 | |||||
| Dividend Payout Ratio | 0.65 | |||||
| 3-Year Dividend Growth Rate | 5.5 | |||||
| Forward Dividend Yield % | 3.52 | |||||
| 5-Year Yield-on-Cost % | 4.3 | |||||
| Shareholder Yield % | 2.87 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 70.18 | |||||
| Operating Margin % | 21.37 | |||||
| Net Margin % | 12.56 | |||||
| FCF Margin % | 13.29 | |||||
| ROE % | 7.44 | |||||
| ROA % | 4.29 | |||||
| ROIC % | 6.69 | |||||
| 3-Year ROIIC % | 3.71 | |||||
| ROC (Joel Greenblatt) % | 49.88 | |||||
| ROCE % | 7.31 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 24.31 | |||||
| Forward PE Ratio | 12.68 | |||||
| PE Ratio without NRI | 18.48 | |||||
| Shiller PE Ratio | 19.59 | |||||
| Price-to-Owner-Earnings | 23.93 | |||||
| PS Ratio | 3.05 | |||||
| PB Ratio | 1.74 | |||||
| Price-to-Tangible-Book | 11.74 | |||||
| Price-to-Free-Cash-Flow | 22.98 | |||||
| Price-to-Operating-Cash-Flow | 14.89 | |||||
| EV-to-EBIT | 20.09 | |||||
| EV-to-Forward-EBIT | 13.01 | |||||
| EV-to-EBITDA | 13.56 | |||||
| EV-to-Forward-EBITDA | 10.74 | |||||
| EV-to-Revenue | 3.38 | |||||
| EV-to-Forward-Revenue | 3.03 | |||||
| EV-to-FCF | 24.69 | |||||
| Price-to-GF-Value | 1.07 | |||||
| Price-to-Projected-FCF | 1.1 | |||||
| Price-to-Median-PS-Value | 1.06 | |||||
| Price-to-Graham-Number | 3.11 | |||||
| Earnings Yield (Greenblatt) % | 4.98 | |||||
| FCF Yield % | 4.36 | |||||
| Forward Rate of Return (Yacktman) % | 2.25 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sanofi SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 44,286 | ||
| EPS (TTM) (€) | 4.43 | ||
| Beta | 0.69 | ||
| 3-Year Sharpe Ratio | 0.09 | ||
| 3-Year Sortino Ratio | 0.12 | ||
| Volatility % | 23.47 | ||
| 14-Day RSI | 84.38 | ||
| 14-Day ATR (€) | 0.607596 | ||
| 20-Day SMA (€) | 103.3035 | ||
| 12-1 Month Momentum % | 16.17 | ||
| 52-Week Range (€) | 85.82 - 106.72 | ||
| Shares Outstanding (Mil) | 1,253.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sanofi SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sanofi SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sanofi SA Frequently Asked Questions
What is Sanofi SA(CHIX:SANp)'s stock price today?
The current price of CHIX:SANp is €106.72. The 52 week high of CHIX:SANp is €106.72 and 52 week low is €85.82.
When is next earnings date of Sanofi SA(CHIX:SANp)?
The next earnings date of Sanofi SA(CHIX:SANp) is 2025-04-24.
Does Sanofi SA(CHIX:SANp) pay dividends? If so, how much?
The Dividend Yield %  of Sanofi SA(CHIX:SANp) is 3.52% (As of Today), Highest Dividend Payout Ratio of Sanofi SA(CHIX:SANp) was 0.82. The lowest was 0.49. And the median was 0.63. The  Forward Dividend Yield % of Sanofi SA(CHIX:SANp) is 3.52%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers